2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH SILKE GILLESSEN
Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH JONATHAN ROSENBERG
Results from CALGB 90601 in Metastatic Urothelial Carcinoma

VIEW ALL ADV BLADDER VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH CORA STERNBERG
SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract

VIEW ALL UTUC VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH TANYA DORFF
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

VIEW ALL mHSPC VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

GU Cancers Symposium 2014 - Heterogeneity and the renal mass biopsy: Its role and reliability - Session Highlights

SAN FRANCISCO, CA USA (UroToday.com) - Dr. Marc Smaldone presented an overview of the role and reliability of renal mass biopsy given the heterogeneity of renal tumors.

Historically there were concerns about sampling error, low negative predictive value, technical failure, procedure-related complications, and biopsy tract seeding. However, modern renal mass biopsy is safe, and accuracy rates greater than 90%, with sensitivities and specificities ranging from 80-92% and 83-100%, respectively, having been reported. The use of renal mass biopsy has increased in the modern era, primarily to identify patients who harbor benign lesions and for whom treatment may be avoided, such as the frail and elderly. 

gucancerssympalt thumbFalse negative biopsy rates in contemporary series are < 5%, and repeat biopsy in non-diagnostic cases has accuracy rates > 80%. Tumor tract seeding, long a feared complication of renal mass biopsy, has a reported incidence of < 0.01%. The largest modern clinical limitation of renal mass biopsy is the inability to differentiate low- from high-risk malignancy by tumor grade. Using core biopsy rather than fine needle aspiration has improved accuracy of renal mass biopsy.

The ability of renal mass biopsy to predict tumor phenotype is uncertain, and recent data illustrate that genomic analyses underestimate the mutational burden of heterogeneous tumors. Improvement in the ability of renal mass biopsy to accurately predict tumor phenotype could impact development of personalized treatment strategies for kidney cancer. As renal mass biopsy has improved, the role of biopsy to help guide individualized therapy has become more clearly defined. In the future, molecular information from renal mass biopsy specimens will be integrated into clinical algorithms to guide patient counseling and inform personalized decision-making.

Highlights of a presentation by Marc C. Smaldone, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Fox Chase Cancer Center, Philadelphia, PA USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe